This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weitz, J. I. Articles by Buller, H. R. Search for Related Content PubMed PubMed Citation Articles by Weitz, J. I. Articles by Buller, H. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Thinners Related Collections Arterial thrombosis Coagulation Thrombin Other anticoagulants Acute coronary syndromes

(Circulation. 2002;105:1004.)
© 2002 American Heart Association, Inc.

Clinical Cardiology: New Frontiers

Direct Thrombin Inhibitors in Acute Coronary Syndromes

Present and Future

Jeffrey I. Weitz, MD; Harry R. Buller, MD, PhD

From McMaster University and Henderson Research Centre, Hamilton, Canada (J.I.W); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands (H.R.B).

Correspondence to Dr Jeffrey Weitz, Henderson Research Centre, 711 Concession St, Hamilton, Ontario L8V 1C3, Canada. E-mail jweitz@thrombosis.hhscr.org

Key Words: thrombin • inhibitors • coronary disease

	Introduction

 
Most acute coronary syndromes are caused by intracoronary thrombus superimposed on disrupted atherosclerotic plaque. Platelets adhere to subendothelial proteins exposed at sites of plaque disruption where they become activated, release vasoactive and procoagulant substances, and aggregate.¹ Tissue factor in the lipid-rich core of the plaque initiates coagulation, which leads to thrombin generation. A potent platelet agonist, thrombin recruits additional platelets to the site of vascular injury. Thrombin also converts fibrinogen to fibrin, which serves to stabilize platelet-rich thrombi formed at sites of plaque disruption. Depending on the extent and duration of coronary artery obstruction, clinical manifestations range from unstable angina to acute myocardial infarction.¹

Aspirin and heparin, the cornerstones of therapy for acute coronary syndromes, reduce the risk of myocardial infarction and death.^2,3 Despite the widespread use of these treatments, however, patients with unstable angina or acute myocardial infarction remain at risk for recurrent ischemic events, suggesting that intracoronary thrombus formation is incompletely attenuated by aspirin and heparin. High concentrations of thrombin are generated by tissue factor exposed at sites of arterial injury.⁴ When bound to fibrin,^5,6 fibrin degradation products,⁷ or subendothelial matrix,⁸ thrombin is resistant to inactivation by the heparin/antithrombin complex. Bound thrombin, which remains enzymatically active, triggers thrombus growth by activating factors V, VIII, and XI,⁹ thereby amplifying thrombin generation. Bound thrombin also activates platelets,¹⁰ at least in part, via thromboxane A₂-independent pathways that are not blocked by aspirin.

Because thrombin plays a central role in arterial thrombogenesis, the goal of most treatment regimens is to block . . . [Full Text of this Article]

This article has been cited by other articles:

				J. I. Weitz, J. Hirsh, and M. M. Samama New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 234S - 256S. [Abstract] [Full Text] [PDF]

				J. C. Fredenburgh, A. R. Stafford, B. A. Leslie, and J. I. Weitz Bivalent Binding to {gamma}A/{gamma}'-Fibrin Engages Both Exosites of Thrombin and Protects It from Inhibition by the Antithrombin-Heparin Complex J. Biol. Chem., February 1, 2008; 283(5): 2470 - 2477. [Abstract] [Full Text] [PDF]

				B. L. Henry, B. H. Monien, P. E. Bock, and U. R. Desai A Novel Allosteric Pathway of Thrombin Inhibition: EXOSITE II MEDIATED POTENT INHIBITION OF THROMBIN BY CHEMO-ENZYMATIC, SULFATED DEHYDROPOLYMERS OF 4-HYDROXYCINNAMIC ACIDS J. Biol. Chem., November 2, 2007; 282(44): 31891 - 31899. [Abstract] [Full Text] [PDF]

				C. M. Gibson, D. A. Morrow, S. A. Murphy, T. M. Palabrica, L. K. Jennings, P. H. Stone, H. H. Lui, T. Bulle, N. Lakkis, R. Kovach, et al. A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2364 - 2373. [Abstract] [Full Text] [PDF]

				J. Hirsh, M. O'Donnell, and J. I. Weitz New anticoagulants Blood, January 15, 2005; 105(2): 453 - 463. [Abstract] [Full Text] [PDF]

				K. A. Tanaka, F. Szlam, N. Katori, N. Sato, J. D. Vega, and J. H. Levy The Effects of Argatroban on Thrombin Generation and Hemostatic Activation In Vitro Anesth. Analg., November 1, 2004; 99(5): 1283 - 1289. [Abstract] [Full Text] [PDF]

				J. Saw, A. M. Lincoff, W. DeSmet, A. Betriu, W. Rutsch, R. G. Wilcox, N. S. Kleiman, K. Wolski, E. J. Topol, and REPLACE-2 Investigators Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: A REPLACE-2 substudy J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1194 - 1199. [Abstract] [Full Text] [PDF]

				J. I. Weitz, J. Hirsh, and M. M. Samama New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 265S - 286S. [Abstract] [Full Text] [PDF]

				Z. Su, A. Vinogradova, A. Koutychenko, D. Tolkatchev, and F. Ni Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors Protein Eng. Des. Sel., August 1, 2004; 17(8): 647 - 657. [Abstract] [Full Text] [PDF]

				H. Ni, J. M. Papalia, J. L. Degen, and D. D. Wagner Control of thrombus embolization and fibronectin internalization by integrin {alpha}IIb{beta}3 engagement of the fibrinogen {gamma} chain Blood, November 15, 2003; 102(10): 3609 - 3614. [Abstract] [Full Text] [PDF]

				E. M. Antman Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions? JAMA, February 19, 2003; 289(7): 903 - 905. [Full Text] [PDF]

				C. K. Derian, B. P. Damiano, M. F. Addo, A. L. Darrow, M. R. D'Andrea, M. Nedelman, H.-C. Zhang, B. E. Maryanoff, and P. Andrade-Gordon Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 855 - 861. [Abstract] [Full Text] [PDF]

				S. R. Lentz Thrombosis of Vein Grafts: Wall Tension Restrains Thrombomodulin Expression Circ. Res., January 10, 2003; 92(1): 12 - 13. [Full Text] [PDF]

				N. R. Bijsterveld, A. H. Moons, S. M. Boekholdt, B. E. van Aken, H. Fennema, R. J.G. Peters, J. C.M. Meijers, H. R. Buller, and M. Levi Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers Circulation, November 12, 2002; 106(20): 2550 - 2554. [Abstract] [Full Text] [PDF]